PHGE
USDBiomX Inc. COmmon Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$0.460
Haut
$0.463
Bas
$0.435
Volume
0.13M
Fondamentaux de l'Entreprise
Capitalisation Boursière
11.5M
Industrie
Biotechnologie
Pays
Israel
Statistiques de Trading
Volume Moyen
0.13M
Bourse
ASE
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
HC Wainwright & Co. Maintains Buy on BiomX, Lowers Price Target to $15
HC Wainwright & Co. analyst Joseph Pantginis maintains BiomX with a Buy and lowers the price target from $21 to $15.
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.